

Nomas Global Investments Llc- S.P.C , Invests USD 612 Million in Beaufond Plc, Eyes Long-Term Strategic Growth.

Nomas Global Investments Llc- S.P.C , a SPV of H. H. Shaikh Mohammed Bin Sultan Bin Hamdan Al Nahyan, a Member of Royal Family of Abu Dhabi.



OFFICE OF
HIS HIGHNESS SHAIKH MOHAMMED BIN SULTAN BIN HAMDAN
AL NAHYAN

PRESS RELEASE

Nomas Global Investments Announces \$612 Million USD Investment in Beaufond Plc.

Abu Dhabi, [November 28, 2024] – Nomas Global Investments LLC-S.P.C, a wholly-owned investment entity of H.H. Sheikh Mohammed Bin Sultan Bin Hamdan Al Nahyan, has announced a strategic investment of \$612 million USD in Beaufond Plc, a leading global pharmaceutical manufacturer. This investment marks a significant milestone in Nomas' commitment to supporting high-growth sectors, including the pharmaceutical industry, in alignment with the UAE's vision for economic diversification and healthcare innovation.

Key Highlights:

- Investment Amount: \$612 million USD
- Valuation: Beaufond is now valued at \$4.36 billion USD
- Strategic Partnership: Expanding Beaufond's global footprint and growth initiatives
- Future Focus: Enhancing local pharmaceutical production and research capabilities

H.H. Sheikh Mohammed Bin Sultan Bin Hamdan Al Nahyan, owner of Nomas Global Investments, stated: “This investment reflects our commitment to supporting strategic industries in the UAE and reinforcing the nation’s position as a global hub for healthcare innovation. Through this partnership, we aim to drive sustainable economic growth and create high-quality job opportunities for UAE nationals.”

A. Kumar, Chief Executive Officer of Beaufond Plc, expressed his gratitude, saying: “We are honored to have Nomas as a strategic partner. This investment will empower us to expand our operations globally and achieve our long-term objectives of delivering innovative and effective medical solutions.”

About Nomas Global Investments

Nomas Global Investments LLC-S.P.C is a private investment entity wholly owned by H.H. Sheikh Mohammed Bin Sultan Bin Hamdan Al Nahyan. Established to invest in high-growth companies within strategic sectors such as pharmaceuticals, technology, and defense, Nomas plays a pivotal role in driving the UAE's economic diversification and industrial growth.

Dubai, United Arab Emirates Dec 12, 2024 ([IssueWire.com](https://www.issuewire.com)) - Beaufond Plc, a leading global pharmaceutical contract manufacturer, is pleased to announce that Nomas Global Investments a SPV of H. H. Shaikh Mohammed Bin Sultan Bin Hamdan Al Nahyan, a Member of Royal Family of Abu Dhabi has signed a Memorandum of Understanding for investment of USD 612 million, acquiring a strategic stake in the company. This investment, made with a long-term growth perspective, values Beaufond at USD 4.36 billion, positioning the company for even greater success in the pharmaceutical sector.

Investment in Beaufond Plc from the member of Royal Family of Abu Dhabi signals a new chapter in the company's journey, as it strengthens its position in the global market and continues to drive forward its mission of delivering high-quality, effective medicines worldwide. The collaboration will further enhance Beaufond's ability to meet the increasing global demand for innovative pharmaceutical products, expand its global footprint, and explore new market opportunities.

Key Highlights:

- **Investment:** USD 612 million from the Royal Family of Abu Dhabi
- **Valuation:** Beaufond is now valued at USD 4.36 billion
- **Strategic Partnership:** Long-term collaboration to support Beaufond's global expansion and growth initiatives
- **Future Focus:** Further strengthening Beaufond's global presence and research capabilities in pharmaceutical manufacturing

Beaufond's Future Plans and Investment in Integrated Formulation Unit: As part of this new strategic phase, Beaufond is also unveiling a major investment in an Integrated Formulation Unit. This facility will focus on the production of solid oral tablets, capsules, ointments, and other oral dosage forms. By consolidating multiple dosage form production processes under one roof, the company will optimize manufacturing efficiency and further enhance Beaufond's ability to deliver high-quality medicines quickly to markets worldwide.

- **Shaikh Mohammed Bin Sultan Bin Hamdan Al Nahyan**, said “ “This investment reflects our commitment to supporting strategic industries in the UAE and reinforcing the nation's position as a global hub for healthcare innovation. Through this partnership, we aim to drive sustainable economic growth and create high-quality job opportunities for UAE nationals.”
- “We are honored and excited to welcome the member of Royal Family of Abu Dhabi as a strategic partner,” said A. Kumar, Coo of Beaufond Plc. “This partnership will provide Beaufond with the resources and support needed to continue our global expansion and achieve our long-term goals. We are equally thrilled to announce our upcoming Integrated Formulation Unit, which will help us meet the growing global demand for safe, effective, and affordable pharmaceutical solutions. This investment further reinforces our commitment to innovation and excellence in the pharmaceutical industry.”

The new Integrated Formulation Unit, is expected to be operational by 2025-2026. This state-of-the-art facility will play a pivotal role in Beaufond's ability to scale its manufacturing capabilities, meet the needs

of an expanding global market, and continue to produce pharmaceutical products that meet the highest international standards for safety and quality.

The project is expected to generate hundreds of new jobs, creating significant economic benefits in the UAE and contributing to the local development of a skilled workforce in the pharmaceutical sector.

About Beaufond Plc

Beaufond Plc is a global leader in pharmaceutical contract manufacturing and multi-commodities trading, known for its high-quality production capabilities across a wide range of therapeutic areas. With more than 15 years of experience, the company has built a strong reputation for delivering effective and accessible Active Pharma Ingredients to markets worldwide. Beaufond focuses on the acquisition, development, and commercialization of branded running products, particularly targeting underserved niche markets. Committed to innovation, compliance, and care, the company continually invests in state-of-the-art facilities and strategic partnerships to maintain its leadership position in the pharmaceutical industry. Over the past several years, Beaufond has transformed into a leading global player through successful business development initiatives, achieving a turnover of USD 2.26 billion in 2024. This success has been driven by new marketing campaigns and enhanced sales support for its diverse product portfolio, strengthening its market presence and fostering sustained growth and profitability for its shareholders. Backed by a strong, experienced leadership team and a capable workforce, Beaufond Plc is well-positioned for continued success.

For more information, please contact: Media & Communication Desk

Christopher Lynn

Email: media.relations@beaufond.com

Media Contact

Beaufond Plc

pr@beaufond.com

Source : Beaufond Plc

[See on IssueWire](#)

